| Trial ID: | L2775 |
| Source ID: | NCT05032001
|
| Associated Drug: |
Biguanide, Dpp4 Inhibitors, Sglt2 Inhibitors
|
| Title: |
ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Abdominal Obesity|Type 2 Diabetes
|
| Interventions: |
DRUG: Biguanide, DPP4 inhibitors, SGLT2 inhibitors
|
| Outcome Measures: |
Primary: Change from baseline in visceral fat measured by bioimpedance in kg at weet twelve, Bioimpedance is a confident method to measured visceral fat, Baseline and week twelve | Other: Change from baseline in A1c level at week twelve, Glycated hemoglobin percentage is the most reliable method to explain glycemic control in type 2 diabetes patients, Baseline and week twelve
|
| Sponsor/Collaborators: |
Sponsor: Metabolic Research Unit
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
30
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2021-08-01
|
| Completion Date: |
2022-08-01
|
| Results First Posted: |
|
| Last Update Posted: |
2021-09-09
|
| Locations: |
Metabolic Research Unit, San Luis Potosi, 78218, Mexico
|
| URL: |
https://clinicaltrials.gov/show/NCT05032001
|
